Lyme Disease and other Tick-Borne Diseases

Number: 0215

  1. Aetna considers outpatient intravenous antibiotic therapy medically necessary in adult and pediatric members with the diagnosis of Lyme disease only when it is based on the clinical presentation of signs and symptoms compatible with the disease and supported by a positive serologic and/or cerebrospinal fluid (CSF) titer by indirect immunofluorescence assay (IFA), Prevue Borrelia burgdorferi antibody detection assay, or enzyme-linked immunosorbent assay (ELISA), which itself is validated by a positive Western Blot Test (see CDC criteria in note* below).

    Once a definitive diagnosis of Lyme disease is established, Aetna considers an initial 4-week course of outpatient intravenous antibiotic therapy medically necessary when any of the following conditions is met:

    1. Lyme arthritis that persists after failing to respond to a 4-week course of appropriate oral antibiotic therapy
    2. Moderate to severe cardiac involvement as evidenced by any of the following:

      1. A 1st-degree heart block with P-R interval greater than 0.4 seconds
      2. Congestive heart failure
      3. Myopericarditis
      4. 2nd- or higher degree atrio-ventricular block
    3. Neurologic involvement of Lyme disease (neuroborreliosis) as evidenced by any of the following:

      1. Encephalopathy/encephalomyelitis
      2. Meningitis confirmed by CSF analysis showing a lymphocytic pleocytosis with evidence of antibody production against Borrelia burgdorferi in the CSF
      3. Sensory/motor radiculoneuropathy or peripheral neuropathy (weakness and/or pain in the extremities or chest)
    4. All cases of Lyme disease in pregnant women who exhibit symptoms and signs of any of the following:

      1. Stage II Lyme disease with early dissemination documented by organ-specific manifestations of infection (arthritic, cardiac, or neurologic)
      2. Stage III late Lyme disease documented by findings of arthritis and/or neurologic complications, such as encephalomyelitis and subacute encephalitis
  2. Aetna considers initial intravenous antibiotic therapy experimental and investigational for the following indications, because the benefit of intravenous antibiotic therapy for these indications has not been established:

    1. Early Lyme disease or new-onset Lyme arthritis
    2. Flu-like syndrome (fatigue, fever, headache, mildly stiff neck, arthralgias, and myalgias)
    3. Non-specific subjective symptoms, such as persistent, chronically debilitating fatigue (chronic fatigue syndrome), difficulty in concentrating, musculoskeletal pain (fibromyalgia), and headache
    4. Prophylaxis in a person who is asymptomatic and the only evidence for Lyme disease is a positive immunologic test (ELISA, IFA, or Western blot)
    5. Mild cardiac involvement of Lyme disease as evidenced by any of the following:

      1. 1st-degree heart block with P-R interval less than 0.4 seconds
      2. Left ventricular dysfunction without congestive heart failure
      3. Transient ST-T depression, T-wave changes
    6. Isolated manifestations of neurologic involvement of Lyme disease (such as Bell's facial nerve palsy/paralysis)
    7. Pregnant woman presenting with localized Lyme disease manifested as a single lesion of erythema migrans without any other symptoms suggestive of disseminated disease
    8. Minor neurologic manifestations of Lyme disease (including headache, stiff neck, and irritability).
  3. Aetna considers the following diagnostic tests for Lyme disease experimental and investigational because there is inadequate scientific evidence to prove their usefulness in clinical practice:

      1. Antigen detection
      2. Borrelia burgdorferi antibody index testing
      3. Borrelia culture
      4. C6 peptide ELISA assay (using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi)
      5. CD57+ lymphocyte counts
      6. Chemokine CXCL13
      7. Complement split products (e.g., C3a and C4a)
      8. Cyst formation
      9. Cytokine analysis
      10. Immune complexes
      11. iSpot Lyme assay
      12. Lymphocyte markers
      13. Lymphocyte transformation test
      14. Measurement of natural killer (NK) cells
      15. Microscope-based assays
      16. Neuroadrenal expanded panel (including histamine, serotonin, and hydroxyindoleacetic acid)
      17. Polymerase chain reaction (PCR) for identification or quantification of Lyme disease (B. burgdorferi) spirochetal DNA or RNA
      18. Positron emission tomography (PET) scanning
      19. Provocative testing (testing for B. burgdorferi after antibiotic provocation)
      20. Serum borreliacidal assay
      21. SPECT scanning
      22. T-cell proliferation response assay
      23. Urine antigen assay
      24. Xenodiagnosis (using the natural tick vector, Ixodes scapularis)
  4. Aetna considers scheduled repeated testing for Lyme disease in a member without a change in signs and symptoms not medically necessary.
  5. Aetna considers one repeat 4-week course of outpatient intravenous antibiotic therapy medically necessary when the member meets all of the following criteria:

    1. The member has met the criteria for an initial course of intravenous antibiotic therapy, using lab results obtained within the past 3 months; and
    2. The member has completed an initial course of appropriate intravenous antibiotic therapy; and
    3. The member has objective evidence of either relapse of infection, progression of Lyme disease organ damage, and/or the finding of a new focus or type of organ damage.

    Aetna considers additional antibiotic therapy in post-treatment, persistently fatigued patients (post-Lyme disease syndrome) experimental and investigational because intravenous antibiotic therapy has not been shown to be effective for this indication.

  6. Concurrent babesiosis or cat-scratch disease is not, in and of itself, considered a medically necessary indication for long-term intravenous antibiotic therapy for Lyme disease.  Long-term intravenous antibiotic therapy is generally not medically necessary in immunocompetent persons with Bartonella-associated vasculo-proliferative diseases (bacillary angiomatosis-peliosis and verruga peruana) or Bartonella bacteriemia (other than Bartonella endocarditis).  Intravenous antibiotic therapy may be medically necessary in persons with severe Bartonella infection, immunocompromised persons, and systemic Bartonella infection complicated by bony or parenchymal involvement or endocarditis

  7. Aetna considers hyperbaric oxygen therapy experimental and investigational for the treatment of Lyme disease because its effectiveness for this indication has not been established (see CPB 0172 - Hyperbaric Oxygen Therapy (HBOT)).

  8. Aetna considers intravenous antibiotic therapy experimental and investigational for the treatment of Q fever because its effectiveness over oral antibiotics for this indication has not been established.

  9. Aetna considers testing ticks for Borrelia burgdorferi experimental and investigational because it has not been proven to be useful for deciding if a person should receive medical treatment following a tick bite.

  10. Aetna considers singlet oxygen therapy experimental and investigational for the treatment of Lyme disease because of a lack of evidence regarding its effectiveness.

  11. Aetna considers chelation therapy experimental and investigational for the treatment of Lyme disease because of a lack of evidence regarding its effectiveness.

  12. Aetna considers intravenous ascorbic acid or intravenous magnesium experimental and investigational for the treatment of Lyme disease because of a lack of evidence regarding their effectiveness.

  13. Aetna considers the use of alpha lipoic acid or “Healing Detox Drips” for the treatment of Lyme disease experimental and investigational because of insufficient evidence of its effectiveness.

*Note: According to the CDC (1995), the recommended method for serologic detection of active disease or previous infection involves a 2-test approach using a sensitive enzyme immunoassay (EIA) or IFA followed by a Western immunoblot.  All specimens positive or equivocal by a sensitive EIA or IFA should be tested by a standardized Western immunoblot.

The CDC (1995) states that when Western immunoblot is used during the first 4 weeks of disease onset (early LD), both immunoglobulin M (IgM) and immunoglobulin G (IgG) procedures should be performed.  However, a positive IgM immunoblot alone is not considered sufficient evidence of active disease in a person with Lyme disease of more than 1 month's duration.  Although the presence of IgM antibodies is useful in evaluating early disease, the CDC states that a positive IgM test result alone is not recommended for use in determining active disease in persons with illness greater than 1 month's duration because the likelihood of a false-positive test result for a current infection is high for these persons.  The following criteria for a positive Western Blot are adapted from the CDC (1995):

IgM immunoblot -- 2 of the following bands are present:

  • 21/22/23/24 kDa (OspC)*
  • 39 kDa (BmpA)
  • 41 kDa (Fla).


IgG immunoblot -- 5 of the following bands are present:

  • 18 kDa
  • 21/22/23/24 kDa (OspC)*
  • 28 kDa
  • 30 kDa
  • 39 kDa (BmpA)
  • 41 kDa (Fla)
  • 45 kDa
  • 58 kDa (not GroEL)
  • 66 kDa
  • 93 kDa.

A positive serology, on its own, is not considered a medically necessary indication for antibiotic therapy for Lyme disease.  According to the CDC, positive antibody tests should be correlated with symptoms to be clinically meaningful.  According to the CDC (1995), if an individual with suspected early Lyme disease has a negative serology, serologic evidence of infection is best obtained by testing of paired acute- and convalescent-phase serum samples.  Serum samples from persons with disseminated or late-stage Lyme disease almost always have a strong IgG response to Borrelia burgdorferi antigens.

* The apparent molecular mass of outer surface protein C (OspC) is strain-dependent; thus the 21 kDa, 22 kDa, 23 kDa, and 24 kDa proteins referred to above are the same.

See also CPB 0206 - Parenteral ImmunoglobulinsCPB 0369 - Chronic Fatigue Syndrome, and CPB 0650 - Polymerase Chain Reaction Testing: Selected Indications


The use and duration of intravenous antibiotic therapy in Lyme disease (LD) remains controversial.  Researchers are currently conducting studies to assess the optimal duration of antibiotic therapy for the various manifestations of LD.  In some areas of the country, patients are being treated for months to 1 year or more with daily parenteral or oral antibiotics.  In a randomized controlled study, Wormser et al (2003) stated that treatment of patients with early LD has trended toward longer duration despite the absence of supporting clinical trials.  These investigators concluded that extending treatment with doxycycline from 10 to 20 days or adding 1 dose of ceftriaxone to the beginning of a 10-day course of doxycycline did not enhance therapeutic efficacy in patients with erythema migrans.  Regardless of regimen, objective evidence of treatment failure was extremely rare.

In the largest long-term study of outcomes based on treatment duration in patients with early LD, Kowalski et al (2010) found that patients treated for 10 days with antibiotic therapy for early LD have long-term outcomes similar to those of patients treated with longer courses.  The investigators found that treatment failure after appropriately targeted short-course therapy, if it occurs, is exceedingly rare.  Kowalski et al (2010) reported on the long-term clinical outcomes of patients with early localized and early disseminated LD based on the duration of antibiotic therapy prescribed.  These investigators reported on a retrospective cohort study and follow-up survey of patients diagnosed as having early localized and early disseminated LD from January 1, 2000 through December 31, 2004 was conducted in a LD-hyperendemic area.  A total of 607 patients met the study inclusion criteria.  Most patients (93 %) were treated with doxycycline for treatment durations of 10 days, 11 to 15 days, or 16 days in 17 %, 33 %, and 47 % of doxycycline-treated patients, respectively.  Treatment failure criteria, defined before performing the study, were met in only 6 patients (1 %).  Although these 6 patients met a priori treatment failure criteria, 4 of these patients' clinical details suggested re-infection, 1 was treated with an inappropriate antibiotic, and 1 developed facial palsy early in therapy.  Re-infection developed in 4 % of patients.  The 2-year treatment failure-free survival rates of patients treated with antibiotics for 10 days, 11 to 15 days, or 16 days were 99.0 %, 98.9 %, and 99.2 %, respectively.  Multiple measures of long-term function -- including pain, general health, and emotional and physical well-being -- were similar among groups.  The only statistically significant difference was decreased social functioning in the group of patients with the longest treatment duration. 

Randomized controlled studies of treatment of patients who remain unwell after standard courses of antibiotic therapy for LD have shown that repeated or prolonged courses of antibiotic therapy are not effective for such patients.  Krupp et al (2003) reported that ceftriaxone therapy in patients with post-Lyme syndrome (PLS) with severe fatigue was associated with an improvement in fatigue but not with cognitive function or an experimental laboratory measure of infection.  Because fatigue (a non-specific symptom) was the only outcome that improved and because treatment was associated with adverse events, these authors concluded that their findings did not support the use of additional antibiotic therapy with intravenous ceftriaxone in post-treatment, persistently fatigued patients with PLS.  This in agreement with the findings of Kaplan et al (2003) who concluded that patients with post-treatment chronic Lyme disease who have symptoms (e.g., fatigue, depression) but show no evidence of persisting Borrelia infection do not show objective evidence of cognitive impairment.  Additional antibiotic therapy was not more beneficial than administering placebo.  Added expense and toxicity are the only proven results of such practice.  Iatrogenic problems, such as gallbladder disease, fungal infections, and other superinfections, and gastrointestinal problems, certainly increase with prolonged use of broad-spectrum antibiotics.  This highlights the need for an appropriate diagnosis before subjecting the patient to antibiotic regimens.

In a randomized, controlled clinical trial, a prolonged course of antibiotics produced no sustained benefit in persons with Lyme encephalopathy.  Fallon et al (2008) reported on a randomized, placebo-controlled trial assessing the efficacy of a 10-week course of intravenous ceftriaxone in patients with a history of clinical LD, as well as current serologic evidence of Borrelia burgdorferi infection, greater than 3 weeks of previous intravenous ceftriaxone therapy completed greater than 4 months before study entry, and objective evidence of memory impairment (but no history of a condition that could confound neuropsychological assessment).  A total of 37 patients with Lyme encephalopathy (out of 3,368 individuals who were screened) were enrolled.  Additionally, 20 healthy control subjects were included to correct for practice effects from repeated neurocognitive testing.  Neuropsychological testing (assessment of motor function, psychomotor function, attention, memory, working memory, and verbal fluency) was conducted at baseline and at weeks 12 and 24 after study entry. At 12 weeks, ceftriaxone recipients showed better cognitive improvement than did placebo recipients (p = 0.053) or healthy controls (p < 0.01) on an aggregate analysis, although not in any single domain.  However, this benefit was not present at 24 weeks.  No benefits were noted on concurrent rheumatologic assessments.  Adverse events related to the study drug or the catheter were seen in 6 of 23 ceftriaxone recipients (26.1 %) and in 1 of 14 placebo recipients (7.1 %).  Commenting on this study, Ellison (2007) said that "[t]he findings that ceftriaxone therapy was not significantly better than placebo, that any benefit was short lived, and that the drug was associated with frequent adverse effects would seem to close the door on any such treatment for Lyme encephalopathy."

The Infectious Diseases Society of America (Wormser et al, 2006) has concluded that there is no scientific evidence to support the need for multiple or very prolonged courses of antibiotics in LD, and that such treatments may cause serious and even fatal adverse effects.

Pfister and Rupprecht (2006) noted that the diagnostic criteria of active neuroborreliosis include inflammatory changes of the cerebrospinal fluid (CSF) and an elevated specific Borrelia CSF-to-serum antibody index, indicating intrathecal Borrelia antibody production.  Patients with neuroborreliosis are usually treated with intravenous ceftriaxone for 2 to 3 weeks.  In case of allergy, doxycycline may be used.  Treatment efficacy is detected by the improvement of the neurological symptoms and the normalization of the CSF pleocytosis.  The measurement of serum and CSF antibodies is not suitable for follow-up, because they frequently persist.  Post-Lyme disease (PLD) syndrome is characterized by persistent complaints and symptoms after previous treatment for Lyme borreliosis, e.g., musculoskeletal or radicular pain, dysaesthesia, and neurocognitive symptoms that are often associated with fatigue.  There is no formal definition of the PLD syndrome, and its pathogenesis is unclear.  Recent controlled studies do not support the use of additional antibiotics in these patients, but recommend primarily symptomatic strategies.  Moreover, Feder et al (2006) stated that antibiotic therapy for more than 8 weeks for patients with LD is not indicated.  Chronic LD due to antibiotic resistant infection has not been demonstrated.  

The diagnosis of LD is valid only in a person with erythema migrans in early LD or for later stages of infection, in a person with a least 1 late manifestation and laboratory confirmation of infection.  Laboratory support of the diagnosis of LD requires detection of specific antibodies to this tick-borne spirochete Borrelia burgdorferi in the serum, either by indirect immunofluorescence assay (IFA) or enzyme-linked immunosorbant assay (ELISA), with the latter now preferred because it is more sensitive and specific.  A Western blot assay that can detect both IgM and IgG antibodies is used to confirm the diagnosis.  Specific IgM antibodies appear first, usually 3 to 4 weeks after the infection begins, while specific IgG antibodies usually appear 6 to 8 weeks after the onset.  An elevated IgM is a value greater than 250 mg/dL and an elevated IgG is a value greater than 1,500 mg/dL.  After peaking, these antibodies subsequently decline after 4 to 6 months of illness.  The critical issue with these antibody tests is that they must be correlated with the timing of the patient's symptoms.  On their own, they are meaningless.

Recent studies have suggested that the C6 ELISA assay, based on a peptide (C6) that reproduces the sequence of invariable region 6 of VlsE, the antigenic variation protein of Borrelia burgdorferi, may improve the sensitivity and standardization of immunoblots for the serologic diagnosis of LD (Marques et al, 2002; Bacon et al, 2003).  In this regard, Wilske (2003) stated that it appears promising to use recombinant proteins (DbpA, VlsE, others) or synthetic peptides (the conserved C6 peptide derived from VlsE) as ELISA antigens for the diagnosis of LD.  However, a recent randomized controlled study reported that C(6) antibody can not be used to assess treatment outcome or the presence of active infection in patients with PLS (Fleming et al, 2004).

The diagnosis of Lyme neuroborreliosis must be validated with evidence of antibody production against Borrelia burgdorferi in the CSF, shown by a higher titer of antibody in the CSF than in the serum.  The most helpful CSF test is intrathecal production of specific antibodies.  This test is run on paired CSF and serum samples and distinguishes intrathecal antibody production from a positive CSF titer due to serum leakage.  A ratio of CSF to serum antibody of greater than 1.0 suggests local central nervous system antibody production and the presence of neuroborreliosis.  With rare exceptions, a positive test documents central nervous system (CNS) invasion by B. burgdorferi.  Other CSF findings suggestive of LD include mild mononuclear pleocytosis and protein elevation.  Studies that are normal or negative include the CSF glucose level, VDRL, and myelin basic protein.  In North American Lyme patients, CSF oligoclonal bands and increased IgG index (very common findings in multiple sclerosis) are unusual.  There are a number of experimental CSF tests that look promising (Borrelia-specific immune complexes, polymerase chain reaction [PCR], antigen detection), but they are available only at a few research centers and have not been validated.

According to evidence-based guidelines, PCR of B. burgdorferi DNA or RNA has not been validated for either the diagnosis of LD or monitoring response to therapy.  Polymerase chain reaction remains a research technique, in part because PCR can become easily contaminated, producing false-positive results.  In addition, no large clinical series have been reported that assess the performance of the test in the non-research setting.  American College of Physicians - American Society of Internal Medicine (ACP-ASIM) guidelines on diagnosis of LD (1997) state that PCR of serum or CSF “need[s] further validation” and that “[p]ublished experience with these techniques [PCR] is insufficient to allow development of guidelines for their use.”  The Centers for Disease Control and Prevention (2001) states that “PCR has not been standardized for routine diagnosis of Lyme Disease.”  The National Institute of Arthritis and Infectious Disease (2001) has explained the reasons why PCR has limited utility in the diagnosis of LD: "To be sure, the polymerase chain reaction (PCR) is an extremely sensitive laboratory test that is capable of detecting very few molecules of bacterial DNA.  However, the numbers of Borrelia likely to be present -- if at all -- in patients suspected of having Lyme disease are too small to generate sufficient amounts of bacterial DNA to be detected by this procedure."

Guidelines on treatment of LD from the Infectious Diseases Society of America (Wormser et al, 2000) do not state any role for PCR in monitoring the treatment of patients with LD.  The American Academy of Pediatrics Committee on Infectious Diseases (2003) stated: "New, more sensitive and more specific diagnostic tests, such as the polymerase chain reaction assay, which may be able to identify the presence of even small quantities of spirochetal DNA, are in development.  However, physicians should be cautious when interpreting results of these investigational tests until their clinical usefulness has been proven."  More recently, the American Academy of Pediatrics Committee on Infectious Diseases (2006) stated that PCR has "no role in diagnosis" of LD.

Persistence of B. burgdorferi sero-reactivity long after LD treatment and cure has led to excesses in therapy and attendant drug- and intravenous line-related morbidity, based on the mistaken assumption that persisting sero-positivity equates with persisting infection.  Laboratory tests should be employed as an adjunct in the diagnosis of LD, used only when specific symptoms suggest substantial likelihood that the disease is present.  Testing as a screening tool should be discouraged.

An incorrect diagnosis of LD is often made, despite negative test results and the absence of findings suggesting LD, because the patient had symptoms compatible with LD.  Some clinicians consider LD a diagnosis of exclusion, and associate any illness compatible with LD as LD.  Because these patients are rarely, if ever, cured by antibiotics, this practice has contributed to an epidemic of anxiety about the chronicity of LD.  The diagnosis is often supposedly confirmed by transient improvement after therapy.  Oral therapy has been shown to elicit placebo responses in as many as 35 % of patients undergoing oral antibiotic therapy, and rates for intravenous therapy might even be higher.

According to the American Academy of Pediatrics Committee on Infectious Diseases (2006): "The widespread practice of ordering serologic tests for patients with nonspecific symptoms such as fatigue or arthralgia who have a low probability of having Lyme disease is not recommended.  Almost all positive serologic test results in these patients are false-positive results.  Patients with acute Lyme disease almost always have objective signs of infection (e.g., erythema migrans, facial nerve palsy, arthritis).  Nonspecific symptoms commonly accompany these specific signs but are almost never the only evidence of Lyme disease."

An incorrect diagnosis of LD can also be made even in the presence of a positive antibody test.  Positive antibody tests are meaningless if not correlated with the duration of the patient's symptoms.  In some instances, patients will be tested repeatedly for Lyme antibodies, until inevitably a false positive result will occur, which is then inappropriately interpreted as evidence of LD and used as justification for prolonged antibiotic therapy.  The degree of clinical response associated with parenteral antibiotic treatment or decreasing serum titers do not correlate with antibiotic success and should not be used as a guide or reason for extended antibiotic administration.  In general, symptoms that persist beyond a full course of parenteral antibiotic therapy generally are not due to continued infection and may actually indicate that the diagnosis is something other than LD.

An editorial summarizing the controversy surrounding the diagnosis and treatment of LD published in the New England Journal of Medicine by the Ad Hoc International Lyme Disease Group (Feder et al, 2007) systematically refuted the arguments behind the diagnosis and treatment of so-called chronic LD.  The Ad Hoc Groupstated that "[c]hronic Lyme disease is the latest in a series of syndromes that have been postulated in an attempt to attribute medically unexplained symptoms to particular infections.  Other examples that have now lost credibility are 'chronic candida syndrome' and 'chronic Epstein–Barr virus infection.'  The assumption that chronic, subjective symptoms are caused by persistent infection with B. burgdorferi is not supported by carefully conducted laboratory studies or by controlled treatment trials.  Chronic Lyme disease, which is equated with chronic B. burgdorferi infection, is a misnomer, and the use of prolonged, dangerous, and expensive antibiotic treatments for it is not warranted."

Whereas early LD, late LD, and PLD symptoms/syndrome are recognized conditions, the term "chronic LD" has recently been popularized by a small number of practitioners (Feder et al, 2007; Chang, 2007).  Chronic, non-specific symptoms (e.g., fatigue, headache, dizziness) are attributed to persistent or incurable B. burgdorferi infection, and patients are subsequently treated with long-term parenteral antibiotics.

Objective manifestations of LD include erythema migrans (the most common presentation of early Lyme disease), certain neurologic and cardiac manifestations, and pauciarticular arthritis (the most common presentation of late LD) (Chang, 2007; Feder et al, 2007).  These symptoms respond well to conventional antibiotic therapy.  Symptoms of PLD include fatigue, musculoskeletal pain, and difficulties with concentration or short-term memory following resolution of objective manifestations of infection.  These symptoms are usually mild, typically resolve within months, and antibiotic therapy is not indicated; when the difficulties persist longer than 6 months, the condition is termed PLD syndrome.  Laboratory testing (usually acute- and convalescent-phase serologies) is a key component of LD diagnosis; in most cases, the testing allows clinicians to confirm evidence of current or past B. burgdorferi infection (Chang, 2007; Feder et al, 2007).

By contrast, chronic LD is the term assigned to patients reporting chronic symptoms without objective clinical, laboratory, or epidemiologic criteria for infection (Chang, 2007; Feder et al, 2007).  They receive chronic parenteral antibiotic therapy for periods of many months to years, despite the absence of any scientific evidence to support this practice.

The Ad Hoc International Lyme Disease Group (Feder et al, 2007) states that chronic antibiotic therapy for chronic LD has resulted in life-threatening anaphylaxis, cholecystectomy after biliary complications from ceftriaxone administration, a fatality due to candidemia from intravenous catheter infection, and other serious adverse events related to intravenous catheters.

The American Academy of Neurology (AAN)'s practice parameter on treatment of nervous system LD (Halperin et al, 2007) provided evidence-based recommendations on the treatment of nervous system LD and PLS.  Three questions were addressed: (i) which anti-microbial agents are effective? (ii) are different regimens preferred for different manifestations of nervous system LD? and (iii) what duration of therapy is needed?  These investigators analyzed published studies (1983 to 2003) using a structured review process to classify the evidence related to the questions posed.  The panel reviewed 353 abstracts; yielding 112 potentially relevant articles that were reviewed, from which 37 articles were identified that were included in the analysis.  The authors concluded that there are sufficient data to conclude that, in both adults and children, this nervous system infection responds well to penicillin, ceftriaxone, cefotaxime, and doxycycline (Level B recommendation).  Although most studies have used parenteral regimens for neuroborreliosis, several European studies support use of oral doxycycline in adults with meningitis, cranial neuritis, and radiculitis (Level B), reserving parenteral regimens for patients with parenchymal CNS involvement, other severe neurological symptomatology, or failure to respond to oral regimens.  The number of children (greater than or equal to 8 years of age) enrolled in rigorous studies of oral versus parenteral regimens has been smaller, making conclusions less statistically compelling.  However, all available data indicate results are comparable to those observed in adults.  In contrast, there is no compelling evidence that prolonged treatment with antibiotics has any beneficial effect in post-Lyme syndrome.

Roos (2007) provided the following comment on (AAN)'s practice parameter on treatment of nervous system LD (Halperin et al, 2007): "Misunderstanding of Lyme disease has created a demand by patients with pain, fatigue, and perceived cognitive trouble to seek prolonged parenteral treatment for Lyme disease and "post-Lyme syndrome."  This study provides evidence-based recommendations for appropriate types and duration of antimicrobial therapy for neurologic Lyme disease.  It also provides reassurance that the disease can be treated and highlights the lack of evidence that post-Lyme syndrome is due to active B. burgdorferi infection that would require prolonged antibiotic therapy."

Testing ticks for Borrelia burgdorferi has not been proven to be useful for deciding if a person should receive medical treatment following a tick bite.  The Centers for Disease Control and Prevention (CDC, 2005) stated that "In general, the identification and testing of individual ticks is not useful for deciding if a persons should get antibiotics following a tick bite".  The California Department of Health Services does not recommend that ticks be tested to determine if treatment is necessary because (i) testing methods vary in accuracy, (ii) the need for treatment should not be based on these test results, and (iii) tick testing results do not necessarily predict if the person bitten will get Lyme disease.  Even if an attached tick tested "negative", other undetected ticks may have attached to a person and transmitted the bacteria.  Additionally, the Rhode Island Department of Health stated that "The testing of ticks for the presence of the bacteria that causes Lyme disease has no role in the clinical diagnosis of Lyme disease".

Concurrent cat-scratch disease or babesiosis is not, in and of itself, justification for long-term antibiotic therapy for LD.  Babesiosis, an infection by a protozoan parasite which in some ways resembling malaria, is most often treated with intravenous or oral clindamycin for 7 days plus oral quinine, or oral atovaquone plus oral azithromycin (Gilbert et al, 2003).

Bartonellosis (infections with Bartonella species) can create symptoms that mimic LD, and in some cases, co-infection can occur.  Bartonella can create granulomatous (cat-scratch disease), bacteremic (Bartonella endocarditis, Oroya fever, and trench fever) or vasculoproliferative disease (bacillary angiomatosis-peliosis and verruga peruana).  According to available guidelines, the diagnosis of both bacillary angiomatosis and cat-scratch disease rests on tissue examination (Warthin-Starry stains) and serologic tests (immunosorbant or ELISA assay).  Bartonella bacteremia is diagnosed with serologic tests and confirmed by blood culture.  Oroya fever may be diagnosed by examining a peripheral blood smear.  According to available guidelines, most patients with cat-scratch disease do not require more than symptomatic support.  A fluctuant or suppurative lymph node may benefit from needle aspiration.  Antibiotic therapy should be reserved for immunocompromised individuals or those with evidence of severe or systemic disease.  Available guidelines state that severe cat-scratch disease is usually treated with oral doxycycline plus rifampin or ciprofloxacin.  Antibiotic therapy for cat-scratch disease should be continued for at least 14 days.  The treatment of choice for bacillary angiomatosis-peliosis is either oral erythromycin or oral doxycycline.  Oral azithromycin is an alternative.  Available guidelines state that patients who are severely ill or unable to absorb oral medications should be treated with intravenous formulations.  Rifampin should be added to the regimen for patients in the former category.  Because disease relapse is otherwise so common in these immunocompromised hosts, patients should be treated for at least 3 months.  Verruga lesions do not respond consistently to anti-microbial agents and sometimes require surgical resection.  Bartonella bacteremia also warrants anti-microbial treatment, despite the fact that some immunocompetent hosts with B. quintana bacteremia will clear their infection spontaneously.  The same drugs for treatment of bacillary angiomatosis-peliosis are recommended for primary bacteremias.  All patients should be evaluated for endocarditis.  According to available guidelines, oral therapy is usually sufficient for uncomplicated Bartonella bacteremia.  Exceptions may include immunocompromised patients, bony or parenchymal involvement, and endocarditis, for which initial parenteral therapy may be advantageous.  Treatment should be administered for at least 6 weeks and for 2 to 4 weeks in patients with and without endocarditis, respectively.  Rifampin should be added to the regimen for treatment of endocarditis.  Available guidelines state that patients with trench fever usually respond rapidly to oral antibiotic therapy with resolution of fever and other symptoms within 1 to 2 days.  Relapses in treated patients have been well described.  In patients with Oroya fever, available guidelines state that that penicillin, chloramphenicol, tetracycline, and streptomycin are effective.  According to these guidelines, oral chloramphenicol for 7 or more days is the therapy of choice because of the frequent association of Salmonella infection in endemic regions.  After the institution of therapy, fever generally disappears within 2 to 3 days, although blood smears may remain positive for some time.

Q fever is caused by Coxiella burnetii (C.b.), an intracellular parasitic gram-negative bacterium.  The most common hosts are goats, cattle, sheep, cats, and occasionally dogs.  This spore-forming microorganism reaches high concentrations in the placenta of infected animals; with aerosolization occurring during parturition.  Human Q fever usually results from inhalation of contaminated aerosol.  There are 3 distinct clinical syndromes of the acute form of Q fever: (i) non-specific febrile illness, (ii) pneumonia, and (iii) hepatitis.  The chronic form of the disease is usually endocarditis, but occasionally it is manifest as hepatitis, osteomyelitis or endovascular infection.  The pneumonic form of the disease can range from very mild to severe pneumonia requiring assisted ventilation.  Diagnosis of Q fever is based on isolation of the agent in cell culture, its direct detection, namely by PCR, and serology.  Detection of high phase II antibodies titers 1 to 3 weeks after the onset of symptoms and identification of IgM antibodies are indicative to acute infection.  High phase I IgG antibody titers of greater than or equal to 1:800 as revealed by micro-immunofluorescence offer evidence of chronic C.b. infection.  For acute Q fever, a 2-week treatment with doxycycline is recommended as the first-line therapy.  In the case of Q fever endocarditis a long-term combined antibiotic therapy (e.g., doxycycline plus quinolones, or doxycycline plus hydroxychloroquine) is necessary to prevent relapses (Maurin and Raoult, 1999; Kovacova and Kazar, 2002; Marrie, 2003).  There is a lack of evidence regarding the use of intravenous antibiotic therapy for patients with Q fever.  A recent review (Parker et al, 2006) did not address the use of intravenous antibiotic therapy for the treatment of Q fever.

Ljostad et al (2007) examined the diagnostic sensitivity and temporal course of intra-thecal Borrelia burgdorferi (Bb) antibody production in acute Lyme neuroborreliosis (LNB).  These researchers recruited consecutive adult patients with LNB diagnosis based on strict selection criteria.  Serum and CSF were obtained, and clinical examination was performed pre-treatment, and 13 days and 4 months post-treatment.  Pre-treatment positive Bb antibody index (AI) was detected in 34 of 43 (79 %).  All 9 pre-treatment Bb AI negative patients, and 26 of 34 pre-treatment Bb AI positive patients reported symptom duration less than 6 weeks.  Eight patients, all Bb AI positive, reported symptom duration of 6 weeks or longer.  Consequently, pre-treatment diagnostic sensitivity of Bb AI was 74 % when symptom duration was less than 6 weeks, and 100 % when 6 weeks or longer.  Three patients converted from negative to positive Bb AI status post-treatment.  The 6 patients who were persistently Bb AI negative had lower CSF cell count and protein at presentation, when compared with the patients with positive Bb AI.  The authors concluded that the diagnostic sensitivity of Bb AI is suboptimal in acute early LNB.  Repeated post-treatment Bb AI testing, to confirm or reject LNB diagnosis, is unreliable, as the majority of initial Bb AI negative patients remained negative at follow-up.

Blanc et al (2007) stated that the AI has a very good specificity but only moderate sensitivity in diagnosing LNB.  These investigators noted that given the lack of consensual criteria for neuroborreliosis and the absence of a "gold standard" diagnostic test, they proposed pragmatic diagnostic criteria for neuroborreliosis, namely the presence of 4 of the following 5 items: (i) no past history of neuroborreliosis, (ii) positive CSF ELISA serology, (iii) positive anti-Borrelia AI, (iv) favorable outcome after specific antibiotic treatment, and (v) no differential diagnosis.  They stated that these new criteria will need to be tested in a larger, prospective cohort.

Orel (1997) described the physico-chemical concept of the singlet oxygen therapy application using photochemically sensibilized air or drinking a water, already barbaturized by an activated singlet oxygen of air.  This technology has been applied in the treatment of several clinical conditions including LD.  However, there is a lack of evidence regarding its effectiveness.

Shoemaker et al (2008) stated that current laboratory markers do not readily detect acute LD.  These researchers assessed the utility of complement and its split products as markers of LD in patients shortly after a tick bite.  A total of 31 consecutive acute LD patients, 14 with and 17 without erythema migrans (EM) skin rash, seen by a physician within 96 hrs of a tick bite were matched with 24 consecutive tick bite patients without LD symptoms and 46 healthy control subjects.  Complement and split products measured included factor B, Bb, C4, C3c, C3a(des Arg), C4a(des Arg), C1q- and C3d-containing immune complexes, and C2.  C2, C4, C3 and factor B levels were within normal ranges in all groups.  C3a and C4a levels were significantly higher in acute LD patients than in tick bite and healthy control groups (both p < 0.001).  All acute LD patients, regardless of EM, had elevated levels of C3a or C4a.  Few tick bite controls had elevated levels of C3a (2/20) or C4a (5/24) and only 1 of the healthy control subjects had elevated C3a (0/46) or C4a (1/32).  The authors concluded that these findings suggested that C3a and C4a may be useful markers of LD in patients seen shortly after tick bite, even in those without EM.  They noted that the findings of this small study need to be confirmed in a larger study with clinical follow-up.  Furthermore, additional studies are needed to evaluate the effects of B. garinii and B. afzelii (which are more common in Europe) infection on the complement system in patients with LD.

Single photon emission computed tomographic (SPECT) scans are often abnormal in patients with LD, but no pattern is specific for LD and these scans are often abnormal in patients without LD (Kalina et al, 2005; Halperin, 2008).  Halperin (2010) stated that SPECT brain scans have been used with increasing frequency.  In one study, quantitative SPECT, applied in a highly selected group of patients with well-characterized nervous system LD, showed patchy brain hypo-metabolism.  However, qualitative brain SPECT, the technique used in clinical laboratories, is highly variable even in normal patients, and has no positive or negative predictive value in nervous system LD.

The European Federation of Neurological Societies' guidelines on the diagnosis and management of European Lyme neuroborreliosis (Mygland et al, 2010) stated that the following 3 criteria should be fulfilled for definite LNB, and 2 of them for possible LNB: (i) neurological symptoms; (ii) CSF pleocytosis; (iii) Bb-specific antibodies produced intra-thecally.  Moreover, PCR and CSF culture may be corroborative if symptom duration is less than 6 weeks, when Bb antibodies may be absent.  Otherwise, PCR is not recommended.  Furthermore, there is insufficient evidence to recommend the following tests for diagnostic purposes: antigen detection, chemokine CXCL13, cyst formation, immune complexes, lymphocyte markers, lymphocyte transformation test, and microscope-based assays.  Adult patients with definite or possible acute LNB (symptom duration less than 6 months) should be offered a single 14-day course of antibiotic treatment.  Oral doxycycline (200 mg daily) and intravenous ceftriaxone (2 g daily) are equally effective in patients with symptoms confined to the peripheral nervous system, including meningitis.  Patients with CNS manifestations should be treated with intravenous ceftriaxone (2 g daily) for 14 days and late LNB (symptom duration greater than 6 months) for 3 weeks.  Children should be treated as adults, except that doxycycline is contraindicated under 8 years of age (9 in some countries).  If symptoms persist for more than 6 months after standard treatment, the condition is often termed PLDS.  Antibiotic therapy has no impact on PLDS.

Marques et al (2009) noted that it has been reported that patients with chronic LD have a decreased number of natural killer (NK) cells, as defined by the CD57 marker.  These researchers performed immunophenotyping in 9 individuals with PLDS, 12 who recovered from LD, and 9 healthy volunteers.  The number of NK cells was not significantly different between the groups.  A review on Lyme borreliosis (Stanek et al, 2012) states that "measurement of the number of CD57 natural killer cells and use of live microscopy on blood to search for spirochaetes, have not been shown to be reliable and are not recommended for clinical use".  Also, an UpToDate review on "Diagnosis of Lyme disease" (Hu, 2012) does not mention measurement of NK cells as a diagnostic tool.

The practice guidelines by the Infectious Diseases Society of America on the "Clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis" (Wormser et al, 2006) did not mention the use of SPECT.  Also, the AAN's practice parameter on "Diagnosis of Patients with Nervous System Lyme Borreliosis" (1996) includes no role for SPECT scans.  A review article by Halperin (2008), who also was the first author of an AAN assessment on this issue, stated that “brain SPECT imaging is notoriously unreliable and is rarely helpful”.

An UpToDate review on "Nervous system Lyme disease" (Halperin, 2011) states that "[s]ince Lyme encephalomyelitis is so rare, MRI of the brain and spine is only rarely abnormal in Lyme disease.  When present, encephalomyelitis is evident on MRI as areas of increased signal on T2 and FLAIR sequences.  When these areas are large and active, positron emission tomography (PET) demonstrates them to be hypermetabolic.  Single photon emission computed tomographic (SPECT) brain scans have been used with increasing frequency.  In one study, quantitative SPECT, applied in a highly selected group of patients with well-characterized nervous system Lyme disease, demonstrated patchy brain hypometabolism.  However qualitative brain SPECT, the technique used in clinical laboratories, is highly variable even in normal patients, and has no positive or negative predictive value in nervous system Lyme disease".  Furthermore, an UpToDate review on "Diagnosis of Lyme disease" (Hu, 2012) does not mention the use of SPECT.

Schmidt et al (2011) examined chemokine CXCL13 as a potential biomarker for LNB.  From March 2008 to August 2009, CSF and serum samples from all patients in whom a B burgdorferi-specific AI was requested (n = 692) and CSF analysis revealed CSF pleocytosis (n = 192) were included in the study.  Because of the low number of patients with untreated LNB, 13 additional retrospectively selected samples of patients with untreated LNB were added.  CXCL13 concentrations were measured by ELISA and receiver operating characteristic curves were generated.  CSF CXCL13 was highly elevated in all patients with untreated acute LNB (mean = 15,149 pg/ml) compared with that in the patients without LNB (mean = 247 pg/ml).  At a cut-off of 1,229 pg/ml, the sensitivity of CXCL13 was 94.1 %, which is higher than the AI (85.7 %).  Only 7 patients (5 with a CNS lymphoma and 2 with bacterial meningitis) had a CXCL13 level above the cut-off, resulting in a specificity equal to the AI of 96.1 %.  The authors concluded that CXCL13 shows high sensitivity and specificity for acute, untreated LNB.  They stated that this novel marker has a high potential for use as a complimentary diagnostic tool for LNB. 

In an editorial that accompanied the afore-mentioned study, Tumani and Cadavid (2011) stated that there are several limitations to the current study: (i) although patients with suspected LNB were prospectively recruited, the number of patients who fulfilled the diagnostic criteria for definite LNB was  small (n = 14), so the conclusions were based on data from a similar number of retrospective cases (n = 13, with CSF samples stored for up to 9 years), (ii) Follow-up of patients with LNB was not performed, and (iii) a commercially available ELISA assay was used, which was calibrated in buffer rather than in CSF, so measurements may not be absolutely accurate or comparable to other assay conditions.  The editorialists noted that "[s]everal important issues remained to be answered with regard to the use of CSF levels of CXCL13 in patients with LNB .... Further studies are also needed to evaluate the usefulness of CSF levels of CXCL13 to determine the optimal duration of antibiotic treatment.  This is of importance especially in cases with suspected "post-Lyme disease", which may represent a major challenge in routine clinical practice and may prompt physicians to use prolonged unjustified antibiotic treatment".

Klempner et al (2013) stated that the authors of 4 National Institutes of Health-sponsored antibiotic treatment trials of patients with persistent unexplained symptoms despite previous antibiotic treatment of Lyme disease determined that re-treatment provided little if any benefit and carries significant risk.  Two groups recently provided an independent re-assessment of these trials and concluded that prolonged courses of antibiotics are likely to be helpful.  These investigators have carefully considered the points raised by these groups, along with their own critical review of the treatment trials.  On the basis of this analysis, the authors concluded that there is a meaningful clinical benefit to be gained from re-treatment of such patients with parenteral antibiotic therapy cannot be justified.

Lantos and colleagues (2014) stated that much of the controversy that surrounds Lyme disease pertains to whether it produces prolonged, treatment-refractory infection, usually referred to as chronic Lyme disease.  Some have proposed that round morphologic variants of B. burgdorferi, known variably as "cyst forms" and "L-forms," are responsible for the pathogenesis of chronic Lyme disease.  These investigators undertook a systematic review of the literature to determine if there is a documented role of these variants in Lyme disease pathogenesis or in syndromes compatible with chronic Lyme disease.  Two systematic literature searches were performed to identify studies in which round morphologic variants of B. burgdorferi have been described in-situ in human specimens.  The primary literature search identified 6 studies that reported round morphologic variants of B. burgdorferi in specimens obtained from 32 total patients.  No study described these forms in patients who had purely subjective symptom complexes (e.g., fatigue or pain).  No study investigated a causal relationship between morphologic variants and clinical disease or evaluated treatment of morphologic variants in-vivo.  Of 29 additional studies that described the morphology of B. burgdorferi from patients with Lyme disease, the organism was invariably described as having spirochetal morphology.  The authors concluded that in the context of the broader medical literature, it is not currently possible to ascribe a pathogenic role to morphologic variants of B. burgdorferi in either typical manifestations of Lyme disease or in other chronic disease states that are often labeled chronic Lyme disease.  They stated that there is no clinical literature to justify specific treatment of B. burgdorferi morphologic variants.

Newberg et al (2002) stated that there were no positron emission tomography (PET) studies reported in the literature with regards to brain metabolism and function in patients with Lyme disease.  These patients frequently present with various neurological symptoms, including memory problems.  These researchers used [(18)F]fluorodeoxyglucose (FDG) PET to determine the metabolic landscape in 23 patients with Lyme disease.  Images were evaluated for cortical and subcortical abnormalities by 2 experienced reviewers blinded to the clinical information.  The most striking finding was hypo-metabolism in the temporal lobes in 17/23 (74 %) patients.  Of these, 12 had bilateral temporal lobe hypo-metabolism, 2 had left temporal lobe, and 3 had right temporal lobe hypo-metabolism.  Seven of the patients with temporal lobe hypo-metabolism had diffuse cortical hypo-metabolism that included the frontal and parietal lobes.  Lyme disease appears to have 2 primary patterns of brain involvement on FDG PET scans, specific temporal lobe hypo-metabolism or a diffuse cortical hypo-metabolism.  The involvement of the temporal lobes in both patterns is likely associated with the memory disturbances described in many of these patients.  The authors concluded that although there was no clear diagnostic pattern, and many of the defects were mild, FDG PET imaging may provide important information regarding the areas of the brain affected in patients with neurological symptoms associated with Lyme disease.

Kalina et al (2005) noted that Lyme disease is a multi-system infectious disease caused by the tick-borne spirochete, B. burgdorferi.  Central nervous system (CNS) involvement typically causes local inflammation, most commonly meningitis, but rarely parenchymal brain involvement.  These investigators described a patient who presented with clinical findings suggesting a brainstem process.  Magnetic resonance imaging (MRI) and PET suggested a brainstem neoplasm.  Prior to biopsy, laboratory evaluation led to the diagnosis of Lyme disease.  Clinical and imaging abnormalities improved markedly following anti-microbial therapy.  The authors described Lyme disease involvement of the cerebellar peduncles with hyper-metabolism on PET.  They stated that although MRI is the primary imaging modality for most suspected CNS pathology, the practical applications of PET continue to expand.

An UpToDate review on “Diagnosis of Lyme disease” (Hu, 2013a) does not mention the use of PET as a management tool.  Furthermore, the review does not mention testing for neuroadrenal expanded panel (including histamine, serotonin, and hydroxyindoleacetic acid (HIAA)).

An UpToDate review on “Treatment of Lyme disease” (Hu, 2013b) does not mention the use of intramuscular antibiotics of intravenous ascorbic acid as therapeutic options.

The iSpot Lyme assay measures cytokine production in-vitro, specifically interferon gamma, from T-cells in response to activation from Lyme antigen.  The interferon-gamma ELISPOT (immunospot) has been used in Lyme disease research since the mid-1990s.  A few scientific papers have investigated its use as a diagnostic test for Lyme disease; however, there is no consensus on its use. 

Norberg et al (2012) examined the diagnostic performance of Borrelia (Bb)-induced interferon (IFN)-gamma secretion detected by ELISPOT modified to be feasible for clinical laboratories as a supplementary test to the laboratory diagnosis of Lyme neuroborreliosis (LNB) in an endemic setting.  Between 2002 and 2004, patients with symptoms of suspected clinical LNB were included in a study conducted on the Aland islands in the Finnish archipelago, which is a hyper-endemic area for Lyme borreliosis (LB).  A total of 14 patients with confirmed LNB and 103 patients with non-LNB were included, and the numbers of spontaneous and Bb-induced IFN-gamma-secreting cells were assayed by the ELISPOT test.  The ELISPOT assay showed a weak diagnostic performance with a sensitivity of 36 % and a specificity of 82 %.  The authors concluded that the findings in this study showed that this ELISPOT-assay modified to be feasible in clinical routine laboratories is not useful as a supplementary diagnostic tool in the laboratory diagnosis of patients with clinically suspected LNB.

Jin et al (2013) noted that Lyme Borreliosis is an infectious disease caused by the spirochete B. burgdorferi that is transmitted through the bite of infected ticks.  Both B cell-mediated humoral immunity and T cell immunity develop during natural Borrelia infection.  However, compared with humoral immunity, the T cell response to Borrelia infection has not been well-elucidated.  In this study, a novel T cell-based assay was developed and validated for the sensitive detection of antigen-specific T cell response to B. burgdorferi.  Using IFN-gamma as a biomarker, these researchers developed a new enzyme-linked immunospot method (iSpot Lyme™) to detect Borrelia antigen-specific effector/memory T cells that were activated in-vivo by exposing them to recombinant Borrelia antigens ex-vivo.  To test this new method as a potential laboratory diagnostic tool, these investigators performed a clinical study with a cohort of Borrelia-positive patients and healthy controls.  They demonstrated that the iSpot Lyme assay has a significantly higher specificity and sensitivity compared with the Western Blot assay that is currently used as a diagnostic measure.  These preliminary findings need to be validated by well-designed studies.

An UpToDate review on “Diagnosis of Lyme disease” (Hu, 2014) does not mention the use of iSpot/cytokine/interferon as a diagnostic tool/biomarker.

Marques noted that animal studies suggested that B. burgdorferi may persist after antibiotic therapy and can be detected by various means including xenodiagnosis using the natural tick vector (Ixodes scapularis).  No convincing evidence exists for the persistence of viable spirochetes after recommended courses of antibiotic therapy in humans.  These researchers determined the safety of using I. scapularis larvae for the xenodiagnosis of B. burgdorferi infection in humans.  Laboratory-reared larval I. scapularis ticks were placed on 36 subjects and allowed to feed to repletion.  Ticks were tested for B. burgdorferi by PCR, culture, and/or isothermal amplification followed by PCR and electrospray ionization mass spectroscopy.  In addition, attempts were made to infect immunodeficient mice by tick bite or inoculation of tick contents.  Xenodiagnosis was repeated in 7 individuals.  Xenodiagnosis was well-tolerated with no severe adverse events.  The most common adverse event was mild itching at the tick attachment site.  Xenodiagnosis was negative in 16 patients with post-treatment Lyme disease syndrome (PTLDS) and/or high C6 antibody levels and in 5 patients after completing antibiotic therapy for erythema migrans.  Xenodiagnosis was positive for B. burgdorferi DNA in 1 patient with erythema migrans early during therapy and in a patient with PTLDS.  There is insufficient evidence, however, to conclude that viable spirochetes were present in either patient.  The authors concluded that xenodiagnosis using Ixodes scapularis larvae was safe and well-tolerated.  They stated that further studies are needed to determine the sensitivity of xenodiagnosis in patients with Lyme disease and the significance of a positive result.

An UpToDate review on “Diagnosis of Lyme disease” (Hu, 2014) states that “Xenodiagnosis for Lyme disease involves the use of a tick vector to detect the presence B. burgdorferi.  Although not clinically available, xenodiagnosis has been used to detect B. burgdorferi in animal and human studies.  In one study, I. scapularis larvae were allowed to feed on 36 human participants (23 with a history of Lyme disease) until the larvae were engorged.  The ticks were then tested for B. burgdorferi by polymerase chain reaction (PCR), culture, and/or isothermal amplification followed by PCR and electrospray ionization mass spectroscopy.  Xenodiagnosis was well tolerated; the most common adverse event was mild itching at the tick attachment site.  Of the 23 patients with a history of Lyme disease, 19 tested negative for B. burgdorferi, two had indeterminate results and two tested positive by PCR, but not by culture.  Of the two who tested positive, one had erythema migrans and was receiving antibiotics, and one had post–treatment Lyme disease.  Further studies are needed to determine the sensitivity of xenodiagnosis in patients with Lyme disease, as well as the significance of a positive result”.

Alpha Lipoic Acid or “Healing Detox Drips” for the Treatment of Lyme Disease:

Puri et al (2015) noted that while pharmacotherapy with intravenous ceftriaxone, a third-generation cephalosporin, is a potential treatment of Lyme neuroborreliosis, there is concern that it can cause the formation of biliary sludge, leading to hepatobiliary complications such as biliary colic, jaundice and cholelithiasis, which are reflected in changes in serum levels of bilirubin and markers of cholestatic liver injury (alkaline phosphatase and gamma-glutamyltranspeptidase).  It has been suggested that the naturally occurring substances alpha-lipoic acid and glutathione may be helpful in preventing hepatic disease.  Alpha-lipoic acid exhibits anti-oxidant, anti-inflammatory and anti-apoptotic activities in the liver, while glutathione serves as a sulfhydryl buffer.  These researchers examined if co-administration of alpha-lipoic acid and glutathione is associated with significant changes in serum levels of bilirubin, alkaline phosphatase and gamma-glutamyltranspeptidase during the treatment of Lyme neuroborreliosis with long-term intravenous ceftriaxone.  Serum levels of bilirubin, alkaline phosphatase and gamma-glutamyltranspeptidase were measured in 42 serologically positive Lyme neuroborreliosis patients before and after long-term treatment with intravenous ceftriaxone (2 to 4 g daily) with co-administration of oral/intravenous alpha-lipoic acid (600 mg daily) and glutathione (100 mg orally or 0.6 to 2.4 g intravenously daily).  None of the patients developed biliary colic and there were no significant changes in serum bilirubin, alkaline phosphatase or gamma-glutamyltranspeptidase levels over the course of the intravenous ceftriaxone treatment (mean length 75.0 days).  The authors concluded that co-administration of alpha-lipoic acid and glutathione is associated with no significant changes in serum bilirubin, alkaline phosphatase or gamma-glutamyltranspeptidase levels during the treatment of neuroborreliosis with intravenous ceftriaxone.

CPT Codes / HCPCS Codes / ICD-10 Codes
Information in the [brackets] below has been added for clarification purposes.   Codes requiring a 7th character are represented by "+":
CPT codes covered if selection criteria are met:
84181 Western Blot, with interpretation and report, blood or other body fluid
84182 Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each
86617 Borrelia burgdorferi (Lyme disease) confirmatory test (e.g., Western Blot or immunoblot)
86618 Borrelia burgdorferi (Lyme disease)
88350 Immunofluorescence, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure)
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
+ 96366     each additional hour, (List separately in addition to code for primary procedure)
+ 96367     additional sequential infusion, up to 1 hour (List separately in addition to code for primary procedure)
+ 96368     concurrent infusion (List separately in addition to code for primary procedure)
96369 Subcutaneous infusion for therapy or prophylaxis (specify substance or drug); initial, up to 1 hour, including pump set-up and establishment of subcutaneous infusion site(s)
+ 96370     each additional hour (List separately in addition to code for primary procedure)
+ 96371     additional pump set-up with establishment of new subcutaneous infusion site(s) (List separately in addition to code for primary procedure)
99601 Home infusion/specialty drug administration, per visit (up to 2 hours)
+ 99602     each additional hour (List separately in addition to code for primary procedure)
CPT codes not covered for indications listed in the CPB:
Alpha lipoic acid or “Healing” Detox Drips – no specific code:
78607 Brain imaging, tomographic (SPECT)
78608 - 78609 Brain imaging, positron emission tomography (PET); metabolic or perfusion evaluation
78811 - 78816 Positron emission tomography (PET)
82136 Amino acids, 2 to 5 amino acids, quantitative, each specimen
82533 Cortisol; total
82626 Dehydroepiandrosterone (DHEA)
83088 Histamine
83497 Hydroxyindolacetic acid, 5-(HIAA)
83520 Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified [chemokine CXCL13] [cytokine analysis]
84260 Serotonin
84681 C-peptide
86160 Complement; antigen, each component [complement split products (e.g., C3a and C4a)]
86161     functional activity, each component [complement split products (e.g., C3a and C4a)]
86162     total hemolytic (ch50) [complement split products (e.g., C3a and C4a)]
86171 Complement fixation tests, each antigen [complement split products (e.g., C3a and C4a)]
86332 Immune complex assay [immune complexes]
86353 Lymphocyte transformation, mitogen (phytomitogen) or antigen induced blastogenesis
86355 B cells, total count [lymphocyte markers]
86357 Natural killer (NK) cells, total count
86359 T cells; total count [lymphocyte markers]
86360 T cells; absolute cd4 and cd8 count including ratio[lymphocyte markers]
87449 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; multiple-step method, not otherwise specified, each organism
88346 Immunofluorescence, per specimen; initial single antibody stain procedure
99183 Physician attendance and supervision of hyperbaric oxygen therapy, per session
HCPCS code covered if selection criteria are met:
S9494 - S9504 Home infusion therapy, antibiotic, antiviral, or antifungal therapy
HCPCS code not covered for indications listed in the CPB:
G0219 PET imaging whole body; melanoma for non-covered indications
G0277 Hyperbaric oxygen under pressure, full body chamber, per 30 minute interval
G0235 PET imaging, any site, not otherwise specified
G0252 PET imaging, full and partial-ring PET scanners only, for initial diagnosis of breast cancer and/or surgical planning for breast cancer (e.g. initial staging of axillary lymph nodes)
J0470 Injection, dimercaprol, per 100 mg
J0600 Injection, edetate calcium disodium, up to 1000 mg
J0895 Injection, deferoxamine mesylate, 500 mg
J3475 Injection, magnesium sulphate, per 500 mg
J3520 Edetate disodium, per 150 mg
M0300 IV chelation therapy (chemical endarterectomy)
S9355 Home infusion therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
ICD-10 code covered if selection criteria are met:
A69.20 Lyme disease, unspecified
ICD-10 code not covered for indications listed in the CPB:
A28.1 Cat-scratch disease
A44.0 - A44.9 Bartonellosis
A78 Q fever
B60.0 Babesiosis
G51.0 Bell's palsy
R53.82 Chronic fatigue, unspecified

The above policy is based on the following references:
    1. Ziller L, Cremer J, Faulde M. Western blot as a tool in the diagnosis of Lyme Boreliosis. Electrophoresis. 1993;14(9):937-944.
    2. Rahn DW, Malawista SE. Lyme disease: Recommendations for diagnosis and treatment. Ann Intern Med. 1991;114(6):472-481.
    3. Sigal LH. Management of Lyme disease refractory to antibiotic therapy. Rheum Dis Clin North Am. 1995;21(1):217-230.
    4. Weber K, Pfister H. Clinical management of Lyme borreliosis. Lancet. 1994;343:1017-1020.
    5. Sigal LH. Management of Lyme disease refractory to antibiotic therapy. Rheum Dis Clin North Am. 1995;21(1):217-230.
    6. Coyle PK, Neurologic complications of Lyme disease. Rheum Dis Clin of North Am. 1993;19(4):993-1009.
    7. Wormser GP. Lyme disease: Insights into the use of antimicrobials for prevention and treatment in the context of experience with other spirochetal infections. Mount Sinai J Med. 1995;62(3):188-195.
    8. Steere AC. Lyme borreliosis. In: Harrison's Principles of Internal Medicine. Vol 1. 13th Ed. New York, NY: McGraw-Hill, Inc; 1996:745-747.
    9. Sigal LH. Persisting symptoms of Lyme disease - possible explanations and implications for treatment. J Rheumatol. 1994;21(4):593-595.
    10. Sigal LH. Persisting complaints attributed to chronic Lyme disease: Possible mechanisms and implications for management. Am J Med. 1994;96(4):365-374.
    11. Wharton M, Chorba TL, Vogt RL, et al. Case definitions for public health surveillance. MMWR Morbid Mortal Wkly Rep. 1990;39(No.RR-13):1-43.
    12. Golightly MG. Laboratory considerations in the diagnosis and management of Lyme Borreliosis. Am J Clin Path. 1993;99(2):168-174.
    13. Rahn DW. Lyme disease. In: Conn's Current Therapy. Philadelphia, PA: W.B. Saunders Company; 1996:119-124.
    14. Nocton JJ. Steere AC. Lyme disease. Advan Intern Med. 1995;40:69-117.
    15. Sigal LH. Lyme disease: Testing and treatment, who should be tested and treated for Lyme disease and how? Rheum Dis Clin North Am. 1993;19(1):79-93.
    16. Cunha BA. Lyme disease. Compr Ther 1993;19(4):135.
    17. Steere AC. Taylor E, McHugh GL, et al. The overdiagnosis of Lyme disease. JAMA. 1993;269(14):1812-1816.
    18. Wormser GP, Nadelman RB, Dattwyler RJ, et al. Practice guidelines for the treatment of Lyme disease. Guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2000;31(Suppl 1):S1-S14.
    19. Lapp T. AAP issues recommendations on the prevention and treatment of Lyme disease. Am Fam Physician. 2000;61(11):3463-3464.
    20. American College of Physicians - American Society of Internal Medicine. Guidelines for laboratory evaluation in the diagnosis of Lyme disease. Clinical Guideline Part 1. Ann Intern Med. 1997;127(12):1106-1108.
    21. Tugwell P, Dennis DT, Weinstein A, et al. Guidelines for laboratory evaluation in the diagnosis of Lyme disease. Clinical Guideline Part 2. Ann Intern Med. 1997;127:1109-1123.
    22. Centers for Disease Control and Prevention (CDC), National Centers for Infectious Diseases (NCID), Division of Vector-Borne Infectious Diseases. Lyme disease. Diagnosis. CDC Lyme Disease Home Page. Fort Collins, CO: NCID; September 19, 2001. Available at: Accessed June 10, 2002.
    23. National Institutes of Health (NIH), National Institute of Arthritis and Infectious Diseases , Division of Microbiology and Infectious Diseases. Diagnosis of Lyme disease. Lyme Disease Research. Bethesda, MD: NIH; January 5, 2001.
    24. Hayes E. Lyme disease. In: Clinical Evidence. London, UK: BMJ Publishing Group; January 2003.
    25. Gilbert DN, Moellering RC, Sande MA, eds. Sanford Guide to Antimicrobial Therapy. 33rd ed. Hyde Park, VT: Antimicrobial Therapy, Inc.; 2003.
    26. Beers MH, Berkow R. Rickettsial diseases. In: The Merck Manual of Diagnosis and Therapy. 17th ed. Centennial Edition. Ch. 159. Whitehouse Station, NJ: Merck & Co.; 1999.
    27. Kamradt T. Lyme disease and current aspects of immunization. Arthritis Res. 2002;4(1):20-29.
    28. Montiel NJ, Baumgarten JM, Sinha AA. Lyme disease--part II: Clinical features and treatment. Cutis. 2002;69(6):443-448.
    29. Centers for Disease Control and Prevention (CDC). Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep. 1995;44(31):590-591.
    30. Pavia CS. Current and novel therapies for Lyme disease. Expert Opin Investig Drugs. 2003;12(6):1003-1016.
    31. Stanek G, Strle F. Lyme borreliosis. Lancet. 2003;362(9396):1639-1647.
    32. Relman DA, Hoesley C, Cobbs CG. Diseases caused by Bartonella species. In: Cecil Textbook of Medicine. 21st ed. L Goldman, JC Bennett, eds. Philadelphia, PA: W.B. Saunders Co.; 2000.
    33. American Academy of Pediatrics (AAP), Committee on Infectious Diseases. Lyme disease (Borrelia burgdorferi infection). In: Red Book: 2003 Report of the Committee on Infectious Diseases. 26th ed. LK Pickering, ed. Elk Grove Village, IL: AAP; 2003.
    34. Long SS, Pickering LK, Prober CG. Principles and Practice of Pediatric Infectious Diseases. 2nd ed. New York, NY: Churchill Livingstone; 2003.
    35. Cohen J, Powderly WG, Berkley SF, et al. Infectious Diseases. 2nd ed. St. Louis, MO: Mosby; 2004.
    36. Mandell GL, Bennett JE, Dolin R. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 5th ed. Philadelphia, PA: Churchill Livingstone; 2000.
    37. Wisconsin Division of Public Health, Bureau of Communicable Diseases. Lyme Disease: Guidelines for Wisconsin Health Care Providers. Madison, WI: Wisconsin Division of Public Health; 1998. Available at:
      LymeClinGuide.pdf. Accessed April 28, 2005.
    38. Marques AR, Martin DS, Philipp MT. Evaluation of the C6 peptide enzyme-linked immunosorbent assay for individuals vaccinated with the recombinant OspA vaccine. J Clin Microbiol. 2002;40(7):2591-2593.
    39. Bacon RM, Biggerstaff BJ, Schriefer ME, et al. Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. J Infect Dis. 2003;187(8):1187-1199.
    40. Wilske B. Diagnosis of lyme borreliosis in Europe. Vector Borne Zoonotic Dis. 2003;3(4):215-227.
    41. Kaplan RF, Trevino RP, Johnson GM, et al. Cognitive function in post-treatment Lyme disease: Do additional antibiotics help? Neurology. 2003;60(12):1916-1922.
    42. Krupp LB, Hyman LG, Grimson R, et al. Study and treatment of post Lyme disease (STOP-LD): A randomized double masked clinical trial. Neurology. 2003;60(12):1923-1930.
    43. Wormser GP, Ramanathan R, Nowakowski J, et al. Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003;138(9):697-704.
    44. Fleming RV, Marques AR, Klempner MS, et al. Pre-treatment and post-treatment assessment of the C(6) test in patients with persistent symptoms and a history of Lyme borreliosis. Eur J Clin Microbiol Infect Dis. 2004;23(8):615-618.
    45. Maurin M, Raoult D. Q fever. Clin Microbiol Rev. 1999;12(4):518-553.
    46. Kovacova E, Kazar J. Q fever--still a query and underestimated infectious disease. Acta Virol. 2002;46(4):193-210.
    47. Marrie TJ. Coxiella burnetii pneumonia. Eur Respir J. 2003;21(4):713-719.
    48. Steffen I, Hirsch HH. Diagnostic tests of Lyme borreliosis. Ther Umsch. 2005;62(11):737-744.
    49. Parker NR, Barralet JH, Bell AM. Q fever. Lancet. 2006;367(9511): 679-688.
    50. Hayes E, Mead P. Lyme disease. In: BMJ Clinical Evidence. London, UK: BMJ Publishing Group; September 2003.
    51. Mogilyansky E, Chien CL, Adelson ME, et al. Comparison of Western immunoblotting and the C6 Lyme assay for laboratory detection of Lyme disease. Clin Diagn Lab Immunol. 2004;11(5):924-929.
    52. Philipp MT, Marques AR, Fawcett PT, et al. C6 test as an indicator fo therapy outcome for patients with disseminated Lyme boreliosis. J Clin Microbiol. 2003;41(11):4955-4960.
    53. Philipp MT, Wormser GP, Marques AR, et al. A decline in C6 antibody titer occurs in successfully treated patient with culture-confirmed early localized or early disseminated Lyme borreliosis. Clin Diagn Lab Immunol. 2005;12(9):1069-1074.
    54. Centers for Disease Control and Prevention (CDC). Lyme disease diagnosis. Health Topics A-Z. Atlanta, GA: CDC; October 7, 2005. Available at: Accessed February 19, 2007.
    55. State of California, Health and Human Services Agency, Department of Health Services (DHS). Testing ticks for Borrelia burgdorferi, the agent of Lyme disease. Questions and answers. Sacramento, CA: DHS; 2006. Available at: Accessed February 19, 2007.
    56. Rhode Island Department of Health. Tick testing for Lyme. Lyme Disease. Providence, RI: Rhode Island Department of Health; 2007. Available at: Accessed February 19, 2007.
    57. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: Clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43(9):1089-1134.
    58. American Academy of Pediatrics, Committee on Infectious Diseases. Lyme disease (Lyme borreliosis, Borrelia burgdorferi infection). In: Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. LK Pickering, CJ Baker, SS Long, JA McMillan, eds. Elk Grove Village, IL: AAP; 2006.
    59. Feder HM Jr, Abeles M, Bernstein M, et al. Diagnosis, treatment, and prognosis of erythema migrans and Lyme arthritis. Clin Dermatol. 2006;24(6):509-520.
    60. Pfister HW, Rupprecht TA. Clinical aspects of neuroborreliosis and post-Lyme disease syndrome in adult patients. Int J Med Microbiol. 2006;296 Suppl 40:11-16.
    61. Feder HM Jr, Johnson BJ, O'Connell S, et al; Ad Hoc International Lyme Disease Group. A critical appraisal of 'chronic Lyme disease'. N Engl J Med. 2007;357(14):1422-1430.
    62. Chang MW. Is 'chronic Lyme disease' real? Journal Watch Dermatology. October 3, 2007. 
    63. Halperin JJ, Logigian EL, Finkel MF, Pearl RA. Practice parameters for the diagnosis of patients with nervous system Lyme borreliosis (Lyme disease). Quality Standards Subcommittee of the American Academy of Neurology.  Neurology. 1996;46(3):619-627.
    64. Halperin JJ, Shapiro ED, Logigian E, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: Treatment of nervous system Lyme disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2007; 69(1):91-102.
    65. Roos KL. AAN practice parameter: Antimicrobial therapy of neuroborreliosis. Journal Watch Neurology, October 2, 2007.
    66. Fallon BA, Keilp JG, Corbera KM, et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology. 2008;70(13):992-1003.
    67. Ellison RT. Antibiotics for Lyme encephalopathy? In a randomized, controlled trial, ceftriaxone produced no sustained benefit. Journal Watch Infectious Diseases, October 31, 2007.
    68. Orel VE. Singlet oxygen therapy. Klin Khir. 1997;(1):47-48.
    69. Ljøstad U, Skarpaas T, Mygland A. Clinical usefulness of intrathecal antibody testing in acute Lyme neuroborreliosis. Eur J Neurol. 2007;14(8):873-876.
    70. Blanc F, Jaulhac B, Fleury M, et al. Relevance of the antibody index to diagnose Lyme neuroborreliosis among seropositive patients. Neurology. 2007;69(10):953-958.
    71. Halperin JJ. Nervous system lyme disease: Diagnosis and treatment. Rev Neurol Dis. 2009;6(1):4-12.
    72. Kowalski TJ, Tata S, Berth W, et al. Antibiotic treatment duration and long-term outcomes of patients with early lyme disease from a lyme disease-hyperendemic area. Clin Infect Dis. 2010;50(4):512-520.
    73. Kalina, P, Decker, A, Kornel, E, Halperin, JJ. Lyme disease of the brainstem. Neuroradiology. 2005;47(12):903-907.
    74. Halperin JJ. Nervous system lyme disease. Infect Dis Clin North Am. 2008;22(2):261-274.
    75. Shoemaker RC, Giclas PC, Crowder C, et al. Complement split products C3a and C4a are early markers of acute lyme disease in tick bite patients in the United States. Int Arch Allergy Immunol. 2008;146(3):255-261.
    76. Halperin JJ. Nervous system Lyme disease. UpToDate [online serial]. Waltham, MA: UpToDate; January, 2012.
    77. Halperin JJ. A tale of two spirochetes: Lyme disease and syphilis. Neurol Clin. 2010;28(1):277-291.
    78. Mygland A, Ljøstad U, Fingerle V, et al; European Federation of Neurological Societies. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol. 2010;17(1):8-16, e1-e4.
    79. Halperin JJ. Nervous system Lyme disease. Infect Dis Clin N Am. 2008;22(2):261–274.
    80. Marques A, Brown MR, Fleisher TA. Natural killer cell counts are not different between patients with post-Lyme disease syndrome and controls. Clin Vaccine Immunol. 2009;16(8):1249-1250.
    81. Schmidt C, Plate A, Angele B, et al. A prospective study on the role of CXCL13 in Lyme neuroborreliosis. Neurology. 2011;76(12):1051-1058.
    82. Tumani H, Cadavid D. Are high CSF levels of CXCL13 helpful for diagnosis of Lyme neuroborreliosis? Neurology. 2011;76(12):1034-1035.
    83. Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. Lancet. 2012;379(9814):461-473.
    84. Hu L. Diagnosis of Lyme disease. UpToDate [online serial]. Waltham, MA: UpToDate; January 2012.
    85. Delong AK, Blossom B, Maloney EL, Phillips SE. Antibiotic retreatment of Lyme disease in patients with persistent symptoms: A biostatistical review of randomized, placebo-controlled, clinical trials. Contemp Clin Trials. 2012;33(6):1132-1142.
    86. Newberg A, Hassan A, Alavi A. Cerebral metabolic changes associated with Lyme disease. Nucl Med Commun. 2002;23(8):773-777.
    87. Kalina P, Decker A, Kornel E, Halperin JJ. Lyme disease of the brainstem. Neuroradiology. 2005;47(12):903-907.
    88. Hu L. Diagnosis of Lyme disease. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed December 2013a.
    89. Hu L. Treatment of Lyme disease [online serial]. Waltham, MA: UpToDate; reviewed December 2013b.
    90. Klempner MS, Baker PJ, Shapiro ED, et al. Treatment trials for post-Lyme disease symptoms revisited. Am J Med. 2013;126(8):665-669.
    91. Lantos PM, Auwaerter PG, Wormser GP. A systematic review of Borrelia burgdorferi morphologic variants does not support a role in chronic Lyme disease. Clin Infect Dis. 2014;58(5):663-671.
    92. Nordberg M, Forsberg P, Nyman D, et al. Can ELISPOT be applied to a clinical setting as a diagnostic utility for neuroborreliosis? Cells. 2012;1(2):153-167.
    93. Jin C, Roen DR, Lehmann PV, Kellermann GH. An enhanced ELISPOT assay for sensitive detection of antigen-specific T cell responses to Borrelia burgdorferi. Cells. 2013;2(3):607-620.
    94. Hu L. Diagnosis of Lyme disease. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed October 2014.
    95. Marques A, Telford SR 3rd, Turk SP, et al. Xenodiagnosis to detect Borrelia burgdorferi infection: A first-in-human study. Clin Infect Dis. 2014;58(7):937-945.
    96. Puri BK, Hakkarainen-Smith JS, Derham A, Monro JA. Co-administration of α-lipoic acid and glutathione is associated with no significant changes in serum bilirubin, alkaline phosphatase or γ-glutamyltranspeptidase levels during the treatment of neuroborreliosis with intravenous ceftriaxone. J Complement Integr Med. 2015;12(3):227-230.

You are now leaving the Aetna website.

Links to various non-Aetna sites are provided for your convenience only. Aetna Inc. and its subsidiary companies are not responsible or liable for the content, accuracy, or privacy practices of linked sites, or for products or services described on these sites.

Continue >